Frederick T. Murphy

2.3k total citations · 1 hit paper
30 papers, 1.8k citations indexed

About

Frederick T. Murphy is a scholar working on Rheumatology, Hematology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Frederick T. Murphy has authored 30 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Rheumatology, 7 papers in Hematology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Frederick T. Murphy's work include Rheumatoid Arthritis Research and Therapies (12 papers), Autoimmune and Inflammatory Disorders Research (7 papers) and Systemic Lupus Erythematosus Research (7 papers). Frederick T. Murphy is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (12 papers), Autoimmune and Inflammatory Disorders Research (7 papers) and Systemic Lupus Erythematosus Research (7 papers). Frederick T. Murphy collaborates with scholars based in United States, Germany and Austria. Frederick T. Murphy's co-authors include Elizabeth C. Hsia, Isabelle Davignon, Michael D. Smith, Christine R. West, Jonathan Kay, Mittie K. Doyle, Josef S Smolen, Eric L. Matteson, Robert Landewé and Yiying Zhou and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and Mayo Clinic Proceedings.

In The Last Decade

Frederick T. Murphy

29 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

2009 423 citations Josef S Smolen, Jonathan Kay et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frederick T. Murphy United States	20	983	434	430	247	246	30	1.8k
Anthony Sebba United States	19	973 1.0×	456 1.1×	397 0.9×	189 0.8×	88 0.4×	37	2.0k
Leena Paimela Finland	27	1.5k 1.6×	505 1.2×	278 0.6×	192 0.8×	236 1.0×	63	2.6k
Simon M. Helfgott United States	22	682 0.7×	207 0.5×	323 0.8×	160 0.6×	101 0.4×	46	1.5k
Nemanja Damjanov Serbia	23	986 1.0×	433 1.0×	410 1.0×	278 1.1×	255 1.0×	95	2.3k
H. M. Markusse Netherlands	18	1.5k 1.5×	552 1.3×	202 0.5×	246 1.0×	372 1.5×	43	2.2k
Wataru Yamamoto Japan	20	535 0.5×	308 0.7×	193 0.4×	191 0.8×	225 0.9×	119	1.6k
Doyt L. Conn United States	28	1.5k 1.6×	344 0.8×	544 1.3×	273 1.1×	294 1.2×	65	2.8k
Sławomir Jeka Poland	22	1.1k 1.2×	409 0.9×	1.1k 2.5×	154 0.6×	120 0.5×	98	2.2k
Jorge Iván Gámez-Nava Mexico	25	916 0.9×	197 0.5×	388 0.9×	81 0.3×	168 0.7×	107	1.8k
Theodoros Dimitroulas Greece	28	971 1.0×	233 0.5×	413 1.0×	65 0.3×	330 1.3×	173	2.6k

Countries citing papers authored by Frederick T. Murphy

Since Specialization

Citations

This map shows the geographic impact of Frederick T. Murphy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederick T. Murphy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederick T. Murphy more than expected).

Fields of papers citing papers by Frederick T. Murphy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frederick T. Murphy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederick T. Murphy. The network helps show where Frederick T. Murphy may publish in the future.

Co-authorship network of co-authors of Frederick T. Murphy

This figure shows the co-authorship network connecting the top 25 collaborators of Frederick T. Murphy. A scholar is included among the top collaborators of Frederick T. Murphy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frederick T. Murphy. Frederick T. Murphy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Husni, M. Elaine, Arthur Kavanaugh, Frederick T. Murphy, et al.. (2019). Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis. Arthritis Care & Research. 72(6). 806–813. 16 indexed citations

Murphy, Frederick T., et al.. (2019). Hydroxychloroquine-induced inverse psoriasis. BMJ Case Reports. 12(2). bcr–2018. 8 indexed citations

Smolen, Josef S, Jonathan Kay, Mittie K. Doyle, et al.. (2015). Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Research & Therapy. 17(1). 14–14. 41 indexed citations

Smolen, Josef S, Jonathan Kay, Robert Landewé, et al.. (2014). 85. Final 5-Year Safety and Efficacy Results of a Phase 3, Randomized, Placebo-Controlled Trial of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy. Lara D. Veeken. 53(suppl_1). i87–i88. 2 indexed citations

Fürst, Daniel E., Jonathan Kay, Mary Chester Wasko, et al.. (2013). The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Lara D. Veeken. 52(10). 1845–1855. 26 indexed citations

Brown, M., et al.. (2013). Tanezumab Reduces Osteoarthritic Hip Pain: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase III Trial. Arthritis & Rheumatism. 65(7). 1795–1803. 106 indexed citations

Wagner, Carrie, Sudha Visvanathan, Michael Elashoff, et al.. (2012). Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Annals of the Rheumatic Diseases. 72(1). 83–88. 49 indexed citations

Smolen, Josef S, Jonathan Kay, Robert Landewé, et al.. (2012). Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Annals of the Rheumatic Diseases. 71(10). 1671–1679. 49 indexed citations

Brown, Mark T., et al.. (2012). Tanezumab Reduces Osteoarthritic Knee Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial. Journal of Pain. 13(8). 790–798. 161 indexed citations

10.

Genovese, Mark C., Chenglong Han, Edward Keystone, et al.. (2012). Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study. The Journal of Rheumatology. 39(6). 1185–1191. 36 indexed citations

11.

Webster, Lynn R., John F. Peppin, Frederick T. Murphy, et al.. (2011). Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. Diabetes Research and Clinical Practice. 93(2). 187–197. 32 indexed citations

12.

Smolen, Josef S, Jonathan Kay, Mittie K. Doyle, et al.. (2009). Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. The Lancet. 374(9685). 210–221. 423 indexed citations breakdown →

13.

Terkeltaub, Robert, John S. Sundy, H. Ralph Schumacher, et al.. (2009). The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Annals of the Rheumatic Diseases. 68(10). 1613–1617. 230 indexed citations

14.

Weinblatt, Michael E., Arthur Kavanaugh, Rubén Burgos‐Vargas, et al.. (2008). Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve‐week, randomized, placebo‐controlled trial. Arthritis & Rheumatism. 58(11). 3309–3318. 267 indexed citations

15.

Wiesenhutter, Craig W., Judith A. Boice, Amy T. Ko, et al.. (2005). Evaluation of the Comparative Efficacy of Etoricoxib and Ibuprofen for Treatment of Patients With Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial. Mayo Clinic Proceedings. 80(4). 470–479. 55 indexed citations

16.

Rincón, Inmaculada del, et al.. (2003). Ethnic variation in the clinical manifestations of rheumatoid arthritis: Role of HLA–DRB1 alleles. Arthritis Care & Research. 49(2). 200–208. 53 indexed citations

17.

Battafarano, Daniel F., et al.. (2002). Validation of the Diesse Mini-Ves Erythrocyte Sedimentation Rate (ESR) Analyzer Using the Westergren ESR Method in Patients With Systemic Inflammatory Conditions. American Journal of Clinical Pathology. 118(1). 14–17. 22 indexed citations

18.

Rincón, Inmaculada del, et al.. (2002). Heterogeneity between men and women in the influence of the HLA–DRB1 shared epitope on the clinical expression of rheumatoid arthritis. Arthritis & Rheumatism. 46(6). 1480–1488. 21 indexed citations

19.

Shorr, Andrew F., Frederick T. Murphy, William R. Gilliland, & Oleh W. Hnatiuk. (2000). Osseous disease in patients with pulmonary sarcoidosis and musculoskeletal symptoms. Respiratory Medicine. 94(3). 228–232. 36 indexed citations

20.

Shorr, Andrew F., Frederick T. Murphy, William F. Kelly, et al.. (1998). Osseous Sarcoidosis Clinical, Radiographic, and Therapeutic Observations. JCR Journal of Clinical Rheumatology. 4(4). 186–192. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact